These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21042038)

  • 1. In vitro and in vivo inhibitory effects of glycyrrhetinic acid on cytochrome P450 3A activity.
    Li HY; Xu W; Su J; Zhang X; Hu LW; Zhang WD
    Pharmacology; 2010; 86(5-6):287-92. PubMed ID: 21042038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
    Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
    Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
    Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
    Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
    Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats.
    Hirunpanich V; Murakoso K; Sato H
    Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms.
    Shayeganpour A; El-Kadi AO; Brocks DR
    Drug Metab Dispos; 2006 Jan; 34(1):43-50. PubMed ID: 16204463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats.
    Zhang W; Tan TM; Lim LY
    Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacodynamic-pharmacokinetic (PD-PK) study on the effects of Danshen (Salvia miltiorrhiza) on midazolam, a model CYP3A probe substrate, in the rat.
    Wang X; Lee WY; Zhou X; Or PM; Yeung JH
    Phytomedicine; 2010 Sep; 17(11):876-83. PubMed ID: 20637580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient inhibition of cyp3a in rats by star fruit juice.
    Hidaka M; Okumura M; Ogikubo T; Kai H; Fujita K; Iwakiri T; Yamasaki K; Setoguchi N; Matsunaga N; Arimori K
    Drug Metab Dispos; 2006 Mar; 34(3):343-5. PubMed ID: 16326816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.
    Katzenmaier S; Markert C; Riedel KD; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2011 Nov; 90(5):666-73. PubMed ID: 21937987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.
    Chen M; Nafziger AN; Bertino JS
    Drug Metab Dispos; 2006 Dec; 34(12):2079-82. PubMed ID: 16997909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.
    Tai W; Gong SL; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Stoch SA; Ma JD
    Drug Metabol Drug Interact; 2013; 28(4):217-23. PubMed ID: 24114901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
    Kurnik D; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
    J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation.
    Nguyen AN; Hoffman JT; Tsunoda SM; Jang IJ; Ma JD
    Int J Clin Pharmacol Ther; 2012 Jul; 50(7):468-75. PubMed ID: 22541751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.